In vitro antimicrobial efficacy of a fixed-dose combination of RHZE against M. tuberculosis
Autor(a) principal: | |
---|---|
Data de Publicação: | 2016 |
Outros Autores: | , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Brazilian Journal of Pharmaceutical Sciences |
Texto Completo: | https://www.revistas.usp.br/bjps/article/view/128355 |
Resumo: | The use of drugs in fixed-dose combination (FDC) is now recommended by the World Health Organization (WHO) due to the emergence of multidrug-resistant strains of Mycobacterium tuberculosis. FDC uses different drugs against tuberculosis (TB) in a single tablet for phase-intensive therapeutic intervention. This therapy aims to optimize treatment, to prevent inappropriate use of drugs, and to prevent the emergence of new resistant strains. This study aims to evaluate the susceptibility of clinical isolates of M. tuberculosis against rifampicin, isoniazid, ethambutol, and pyrazinamide. The antimicrobials were tested separately and in associations according to FDC. This was used for broth microdilution method, which was compared to the proportions method previously considered as the gold standard. In antimicrobials testing alone, several strains were resistant to one, two, or three drugs. However, when applied to association of drugs in FDC, there was no antimicrobial resistance. The results strengthen the FDC's concept, which aims to unite the four anti-TB drugs to combat bacterial resistance. |
id |
USP-31_ab66c431ce2ae5e79539f06fa73a1904 |
---|---|
oai_identifier_str |
oai:revistas.usp.br:article/128355 |
network_acronym_str |
USP-31 |
network_name_str |
Brazilian Journal of Pharmaceutical Sciences |
repository_id_str |
|
spelling |
In vitro antimicrobial efficacy of a fixed-dose combination of RHZE against M. tuberculosis The use of drugs in fixed-dose combination (FDC) is now recommended by the World Health Organization (WHO) due to the emergence of multidrug-resistant strains of Mycobacterium tuberculosis. FDC uses different drugs against tuberculosis (TB) in a single tablet for phase-intensive therapeutic intervention. This therapy aims to optimize treatment, to prevent inappropriate use of drugs, and to prevent the emergence of new resistant strains. This study aims to evaluate the susceptibility of clinical isolates of M. tuberculosis against rifampicin, isoniazid, ethambutol, and pyrazinamide. The antimicrobials were tested separately and in associations according to FDC. This was used for broth microdilution method, which was compared to the proportions method previously considered as the gold standard. In antimicrobials testing alone, several strains were resistant to one, two, or three drugs. However, when applied to association of drugs in FDC, there was no antimicrobial resistance. The results strengthen the FDC's concept, which aims to unite the four anti-TB drugs to combat bacterial resistance. Universidade de São Paulo. Faculdade de Ciências Farmacêuticas2016-09-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/bjps/article/view/12835510.1590/s1984-82502016000300022Brazilian Journal of Pharmaceutical Sciences; Vol. 52 Núm. 3 (2016); 575-580Brazilian Journal of Pharmaceutical Sciences; v. 52 n. 3 (2016); 575-580Brazilian Journal of Pharmaceutical Sciences; Vol. 52 No. 3 (2016); 575-5802175-97901984-8250reponame:Brazilian Journal of Pharmaceutical Sciencesinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/bjps/article/view/128355/125227Copyright (c) 2018 Brazilian Journal of Pharmaceutical Sciences (Impresso)info:eu-repo/semantics/openAccessAgertt, Vanessa AlbertinaBonez, Pauline CordenonsiMizdal, Caren RigonRossi, Grazielle GuidolinFlores, Vanessa da CostaCampos, Marli Matiko Anraku de2017-03-16T17:54:51Zoai:revistas.usp.br:article/128355Revistahttps://www.revistas.usp.br/bjps/indexPUBhttps://old.scielo.br/oai/scielo-oai.phpbjps@usp.br||elizabeth.igne@gmail.com2175-97901984-8250opendoar:2017-03-16T17:54:51Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP)false |
dc.title.none.fl_str_mv |
In vitro antimicrobial efficacy of a fixed-dose combination of RHZE against M. tuberculosis |
title |
In vitro antimicrobial efficacy of a fixed-dose combination of RHZE against M. tuberculosis |
spellingShingle |
In vitro antimicrobial efficacy of a fixed-dose combination of RHZE against M. tuberculosis Agertt, Vanessa Albertina |
title_short |
In vitro antimicrobial efficacy of a fixed-dose combination of RHZE against M. tuberculosis |
title_full |
In vitro antimicrobial efficacy of a fixed-dose combination of RHZE against M. tuberculosis |
title_fullStr |
In vitro antimicrobial efficacy of a fixed-dose combination of RHZE against M. tuberculosis |
title_full_unstemmed |
In vitro antimicrobial efficacy of a fixed-dose combination of RHZE against M. tuberculosis |
title_sort |
In vitro antimicrobial efficacy of a fixed-dose combination of RHZE against M. tuberculosis |
author |
Agertt, Vanessa Albertina |
author_facet |
Agertt, Vanessa Albertina Bonez, Pauline Cordenonsi Mizdal, Caren Rigon Rossi, Grazielle Guidolin Flores, Vanessa da Costa Campos, Marli Matiko Anraku de |
author_role |
author |
author2 |
Bonez, Pauline Cordenonsi Mizdal, Caren Rigon Rossi, Grazielle Guidolin Flores, Vanessa da Costa Campos, Marli Matiko Anraku de |
author2_role |
author author author author author |
dc.contributor.author.fl_str_mv |
Agertt, Vanessa Albertina Bonez, Pauline Cordenonsi Mizdal, Caren Rigon Rossi, Grazielle Guidolin Flores, Vanessa da Costa Campos, Marli Matiko Anraku de |
description |
The use of drugs in fixed-dose combination (FDC) is now recommended by the World Health Organization (WHO) due to the emergence of multidrug-resistant strains of Mycobacterium tuberculosis. FDC uses different drugs against tuberculosis (TB) in a single tablet for phase-intensive therapeutic intervention. This therapy aims to optimize treatment, to prevent inappropriate use of drugs, and to prevent the emergence of new resistant strains. This study aims to evaluate the susceptibility of clinical isolates of M. tuberculosis against rifampicin, isoniazid, ethambutol, and pyrazinamide. The antimicrobials were tested separately and in associations according to FDC. This was used for broth microdilution method, which was compared to the proportions method previously considered as the gold standard. In antimicrobials testing alone, several strains were resistant to one, two, or three drugs. However, when applied to association of drugs in FDC, there was no antimicrobial resistance. The results strengthen the FDC's concept, which aims to unite the four anti-TB drugs to combat bacterial resistance. |
publishDate |
2016 |
dc.date.none.fl_str_mv |
2016-09-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.revistas.usp.br/bjps/article/view/128355 10.1590/s1984-82502016000300022 |
url |
https://www.revistas.usp.br/bjps/article/view/128355 |
identifier_str_mv |
10.1590/s1984-82502016000300022 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://www.revistas.usp.br/bjps/article/view/128355/125227 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2018 Brazilian Journal of Pharmaceutical Sciences (Impresso) info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2018 Brazilian Journal of Pharmaceutical Sciences (Impresso) |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Universidade de São Paulo. Faculdade de Ciências Farmacêuticas |
publisher.none.fl_str_mv |
Universidade de São Paulo. Faculdade de Ciências Farmacêuticas |
dc.source.none.fl_str_mv |
Brazilian Journal of Pharmaceutical Sciences; Vol. 52 Núm. 3 (2016); 575-580 Brazilian Journal of Pharmaceutical Sciences; v. 52 n. 3 (2016); 575-580 Brazilian Journal of Pharmaceutical Sciences; Vol. 52 No. 3 (2016); 575-580 2175-9790 1984-8250 reponame:Brazilian Journal of Pharmaceutical Sciences instname:Universidade de São Paulo (USP) instacron:USP |
instname_str |
Universidade de São Paulo (USP) |
instacron_str |
USP |
institution |
USP |
reponame_str |
Brazilian Journal of Pharmaceutical Sciences |
collection |
Brazilian Journal of Pharmaceutical Sciences |
repository.name.fl_str_mv |
Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP) |
repository.mail.fl_str_mv |
bjps@usp.br||elizabeth.igne@gmail.com |
_version_ |
1800222912850952192 |